ASTEX PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 136
- Market Cap
- -
- Website
- http://www.astx.com
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT02920008
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇸🇪Sahlgrenska University Hospital, Göteborg, Sweden
🇬🇧Heart of England NHS Foundation Trust - Heartlands Hospital, Birmingham, United Kingdom
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 417
- Registration Number
- NCT02907359
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
- Conditions
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 815
- Registration Number
- NCT02348489
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇺🇸University of Chicago, Chicago, Illinois, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT02103478
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01752933
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
🇨🇦Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT01712217
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University The Feinberg School of Medicine, Chicago, Illinois, United States
SGI-110 in Combination With Carboplatin in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01696032
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center- University of Southern California, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01685268
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸Clinical Research Alliance, Inc., Lake Success, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01357395
- Locations
- 🇵🇱
Wojewódzki Szpital Specjalistyczny, Radom, Mazowieckie, Poland
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01294202
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States